Earnings Surprises

Biggest EPS beats and misses, ranked by post-earnings price reaction. Free data, no paywall.

Q3 2026 Season
60% beat EPS(vs Q2 2026: 60% beat)Avg surprise: +7.0%Avg reaction: -1.0%22% raised guidance5% lowered464/503 S&P 5004,118 reported

Beats and misses reported Oct 1 – Nov 18, 2026

Biggest EPS Beats25

Ranked by EPS surprise % (highest first). Price reaction = day after report.

#SymbolCompanySectorDateEPS ActualEPS Est.SurprisePrice Reaction
1iRhythm Technologies, Inc.HealthcareNov 5, 2026$0.82↑ Raised$0.02+5190%-32.7%
Quentin Blackford, President and Chief Executive Officer

Our third quarter results reflect the continued strength of our core business. Demand for Zio Monitor remains robust, exceeding our expectations in the quarter, driven by volume growth across care settings and channels.

2Legend Biotech CorporationHealthcareNov 10, 2026$0.14$0.01+1300%-16.0%
3Alnylam Pharmaceuticals, Inc.HealthcareOct 29, 2026$16.26$1.66+880%-25.1%
4Centene Corp.HealthcareOct 27, 2026$0.58↑ Raised$0.10+506%+1.0%
Sarah M. London, Chief Executive Officer

Solid underlying fundamentals within our core businesses have powered a faster recovery to our earnings trajectory than previously anticipated,

5AMN Healthcare Services, Inc.HealthcareNov 5, 2026$1.16↓ Lowered$0.23+406%-24.2%
Cary Grace, President and Chief Executive Officer

We are encouraged by the continued growth in nursing and allied staffing. Demand strengthened during the third quarter and through October and our team is delivering for our clients through faster recruiting, automation,

6Vericel CorporationHealthcareNov 5, 2026$0.27↑ Raised$0.06+371%+20.1%
Nick Colangelo, President and CEO

The Company delivered outstanding financial and business results in the third quarter as we continue to generate top-tier revenue and profit growth as well as significant free cash flow, while also returning capital to shareholders.

7GeneDx Holdings Corp.HealthcareNov 9, 2026$0.28— Maintained$0.07+284%-16.6%
Katherine Stueland, CEO

Our Q3 results reflect profitable execution in a growing market, as we translate the rising demand for exome and genome testing into durable revenue growth.

8Omeros CorporationHealthcareNov 16, 2026$0.06$0.02+200%-16.6%
9CareDx, IncHealthcareOct 29, 2026$0.70↑ Raised$0.25+175%+22.2%
John Hanna, President and Chief Executive Officer

We delivered another strong quarter of solid execution, with continued growth in Transplant, progress scaling Specialty Oncology, and important advances across our pipeline and clinical evidence, including in Cell Therapy.

10Azenta, Inc.HealthcareNov 10, 2026$0.28~ Mixed$0.11+152%+20.8%
Dr. Martin Madaus, Interim President and Chief Executive Officer

We closed fiscal 2026 with improving momentum, delivering stronger performance in the second half of the year. Our businesses have strong market positions and differentiated capabilities, and we are seeing progress from our efforts to improve commercial execution and operating efficiency,

11Privia Health Group, Inc.HealthcareNov 5, 2026$0.21↑ Raised$0.09+132%+9.0%
12BillionToOne, Inc.HealthcareNov 4, 2026$0.32↑ Raised$0.15+119%+1.8%
Dr. Oguzhan Atay, Co-Founder and CEO

Our third quarter was another period of strong execution, said Dr. Oguzhan Atay, Co-Founder and CEO of BillionToOne. We delivered rapid growth with continued GAAP profitability, and more clinicians are choosing our tests in both prenatal and oncology.

13STAAR Surgical CompanyHealthcareNov 4, 2026$0.11$0.05+117%+6.2%

As we look ahead, our results give us the confidence to raise our ambitions. EVO ICL redefined the refractive landscape and is leading a market shift from laser to lens.

14BeOne Medicines AGHealthcareNov 5, 2026$4.59↑ Raised$2.34+96.2%+7.7%
John V. Oyler, Co-Founder, Chairman, and CEO

Our strong third quarter results and raised full-year guidance reflect continued rapid global growth and leadership in hematology, anchored by our foundational BTK inhibitor BRUKINSA.

15Xeris Biopharma Holdings, Inc.HealthcareNov 5, 2026$0.06↑ Raised$0.03+89.3%+45.3%
John Shannon, Chairman and Chief Executive Officer

As a biopharmaceutical leader in endocrine and rare diseases, our strong third quarter performance puts us on a new growth curve that is accelerating our Company's near-term outlook

16Caris Life Sciences, Inc.HealthcareNov 4, 2026$0.05↑ Raised$0.03+77.9%-21.6%
David Dean Halbert, Founder, Chairman and CEO

This was another record quarter, with approximately 61,500 clinical cases, up 21% year over year, said David Dean Halbert, Founder, Chairman and CEO of Caris Life Sciences.

17Neurocrine Biosciences, Inc.HealthcareNov 2, 2026$3.29↑ Raised$1.91+72.3%+13.4%
Kyle W. Gano, Ph.D., Chief Executive Officer

Our third quarter performance marks another important milestone in Neurocrine's evolution, with net product sales exceeding $1 billion for the first time, driven by strong underlying demand across our diversified portfolio of first-in-class medicines.

18TransMedics Group, Inc.HealthcareNov 5, 2026$0.51↑ Raised$0.30+71.4%+21.3%
Waleed Hassanein, MD, President and Chief Executive Officer

The third quarter of 2026 was the strongest in TransMedics' history, with record revenue and record case volume. Importantly, we delivered these results despite typical third quarter seasonality and before any contribution from ENHANCE Part B or DENOVO.

19Progyny, Inc.HealthcareNov 4, 2026$0.52↑ Raised$0.31+66.1%+18.3%
Pete Anevski, Chief Executive Officer

We're exceptionally pleased with the results of our most recent selling season, where our momentum extended even into its latest stages, yielding 1.3 million new covered lives, our most ever in a single season

20Sarepta Therapeutics, Inc.HealthcareNov 5, 2026$0.13↑ Raised$0.08+64.6%-6.2%
Michael Severino, M.D., chief executive officer

After my first 90 days at Sarepta, I believe the fundamental strengths that attracted me to the company remain firmly intact: a durable Duchenne franchise, a promising pipeline with the potential to deliver differentiated medicines, and the financial strength to invest in our highest-value opportunities.

21InnovAge Holding Corp.HealthcareNov 3, 2026$0.14— Maintained$0.09+63.0%+9.8%
Patrick Blair, Chief Executive Officer

We are pleased with our strong start to fiscal 2027, as continued census growth along with disciplined clinical and operational execution drove strong financial performance.

22LifeStance Health Group, Inc.HealthcareNov 5, 2026$0.06↑ Raised$0.04+62.6%-3.1%
Dave Bourdon, CEO

The team delivered a tremendous quarter, with execution across the business driving results that once again exceeded our expectations," said Dave Bourdon, CEO of LifeStance.

23Inspire Medical Systems, Inc.HealthcareNov 2, 2026$0.14↓ Lowered$0.09+60.9%-7.9%
Tim Herbert, Chairman and CEO

Looking further ahead, we were also pleased with the AMA Editorial Panel's September approval of a new CPT code for single lead HGNS devices, including the Inspire V system.

24Eton Pharmaceuticals, Inc.HealthcareNov 5, 2026$0.50↑ Raised$0.31+60.0%+11.3%
Sean Brynjelsen, CEO

Eton delivered another record quarter, with revenue of $57.9 million, up 158% year over year, and surpassed our $200 million annualized revenue run rate goal five quarters ahead of schedule.

25AxoGen, Inc.HealthcareOct 28, 2026$0.21↑ Raised$0.13+59.9%+31.5%
Michael Dale, President and CEO

We are delighted with our third-quarter and year-to-date revenue performance and the progress we continue to make across each of Axogen's strategic plan priorities,

IRTC logo1IRTCiRhythm Technologies, Inc.Nov 5, 2026
Mkt Cap$3.1B
EPS Act.$0.82
EPS Est.$0.02
Surprise+5190%
Reaction-32.7%
SectorHealthcare
Quentin Blackford, President and Chief Executive Officer

Our third quarter results reflect the continued strength of our core business. Demand for Zio Monitor remains robust, exceeding our expectations in the quarter, driven by volume growth across care settings and channels.

LEGN logo2LEGNLegend Biotech CorporationNov 10, 2026
Mkt Cap$3.0B
EPS Act.$0.14
EPS Est.$0.01
Surprise+1300%
Reaction-16.0%
SectorHealthcare
ALNY logo3ALNYAlnylam Pharmaceuticals, Inc.Oct 29, 2026
Mkt Cap$19.9B
EPS Act.$16.26
EPS Est.$1.66
Surprise+880%
Reaction-25.1%
SectorHealthcare
CNC logo4CNCCentene Corp.Oct 27, 2026
Mkt Cap$33.3B
EPS Act.$0.58
EPS Est.$0.10
Surprise+506%
Reaction+1.0%
SectorHealthcare
Sarah M. London, Chief Executive Officer

Solid underlying fundamentals within our core businesses have powered a faster recovery to our earnings trajectory than previously anticipated,

AMN logo5AMNAMN Healthcare Services, Inc.Nov 5, 2026
Mkt Cap$1.5B
EPS Act.$1.16
EPS Est.$0.23
Surprise+406%
Reaction-24.2%
SectorHealthcare
Cary Grace, President and Chief Executive Officer

We are encouraged by the continued growth in nursing and allied staffing. Demand strengthened during the third quarter and through October and our team is delivering for our clients through faster recruiting, automation,

VCEL logo6VCELVericel CorporationNov 5, 2026
Mkt Cap$3.0B
EPS Act.$0.27
EPS Est.$0.06
Surprise+371%
Reaction+20.1%
SectorHealthcare
Nick Colangelo, President and CEO

The Company delivered outstanding financial and business results in the third quarter as we continue to generate top-tier revenue and profit growth as well as significant free cash flow, while also returning capital to shareholders.

WGS logo7WGSGeneDx Holdings Corp.Nov 9, 2026
Mkt Cap$1.5B
EPS Act.$0.28
EPS Est.$0.07
Surprise+284%
Reaction-16.6%
SectorHealthcare
Katherine Stueland, CEO

Our Q3 results reflect profitable execution in a growing market, as we translate the rising demand for exome and genome testing into durable revenue growth.

OMER logo8OMEROmeros CorporationNov 16, 2026
Mkt Cap$1.1B
EPS Act.$0.06
EPS Est.$0.02
Surprise+200%
Reaction-16.6%
SectorHealthcare
CDNA logo9CDNACareDx, IncOct 29, 2026
Mkt Cap$3.8B
EPS Act.$0.70
EPS Est.$0.25
Surprise+175%
Reaction+22.2%
SectorHealthcare
John Hanna, President and Chief Executive Officer

We delivered another strong quarter of solid execution, with continued growth in Transplant, progress scaling Specialty Oncology, and important advances across our pipeline and clinical evidence, including in Cell Therapy.

AZTA logo10AZTAAzenta, Inc.Nov 10, 2026
Mkt Cap$2.2B
EPS Act.$0.28
EPS Est.$0.11
Surprise+152%
Reaction+20.8%
SectorHealthcare
Dr. Martin Madaus, Interim President and Chief Executive Officer

We closed fiscal 2026 with improving momentum, delivering stronger performance in the second half of the year. Our businesses have strong market positions and differentiated capabilities, and we are seeing progress from our efforts to improve commercial execution and operating efficiency,

PRVA logo11PRVAPrivia Health Group, Inc.Nov 5, 2026
Mkt Cap$3.1B
EPS Act.$0.21
EPS Est.$0.09
Surprise+132%
Reaction+9.0%
SectorHealthcare
BLLN logo12BLLNBillionToOne, Inc.Nov 4, 2026
Mkt Cap$4.2B
EPS Act.$0.32
EPS Est.$0.15
Surprise+119%
Reaction+1.8%
SectorHealthcare
Dr. Oguzhan Atay, Co-Founder and CEO

Our third quarter was another period of strong execution, said Dr. Oguzhan Atay, Co-Founder and CEO of BillionToOne. We delivered rapid growth with continued GAAP profitability, and more clinicians are choosing our tests in both prenatal and oncology.

STAA logo13STAASTAAR Surgical CompanyNov 4, 2026
Mkt Cap$1.3B
EPS Act.$0.11
EPS Est.$0.05
Surprise+117%
Reaction+6.2%
SectorHealthcare

As we look ahead, our results give us the confidence to raise our ambitions. EVO ICL redefined the refractive landscape and is leading a market shift from laser to lens.

ONC logo14ONCBeOne Medicines AGNov 5, 2026
Mkt Cap$43.1B
EPS Act.$4.59
EPS Est.$2.34
Surprise+96.2%
Reaction+7.7%
SectorHealthcare
John V. Oyler, Co-Founder, Chairman, and CEO

Our strong third quarter results and raised full-year guidance reflect continued rapid global growth and leadership in hematology, anchored by our foundational BTK inhibitor BRUKINSA.

XERS logo15XERSXeris Biopharma Holdings, Inc.Nov 5, 2026
Mkt Cap$2.9B
EPS Act.$0.06
EPS Est.$0.03
Surprise+89.3%
Reaction+45.3%
SectorHealthcare
John Shannon, Chairman and Chief Executive Officer

As a biopharmaceutical leader in endocrine and rare diseases, our strong third quarter performance puts us on a new growth curve that is accelerating our Company's near-term outlook

CAI logo16CAICaris Life Sciences, Inc.Nov 4, 2026
Mkt Cap$5.5B
EPS Act.$0.05
EPS Est.$0.03
Surprise+77.9%
Reaction-21.6%
SectorHealthcare
David Dean Halbert, Founder, Chairman and CEO

This was another record quarter, with approximately 61,500 clinical cases, up 21% year over year, said David Dean Halbert, Founder, Chairman and CEO of Caris Life Sciences.

NBIX logo17NBIXNeurocrine Biosciences, Inc.Nov 2, 2026
Mkt Cap$16.4B
EPS Act.$3.29
EPS Est.$1.91
Surprise+72.3%
Reaction+13.4%
SectorHealthcare
Kyle W. Gano, Ph.D., Chief Executive Officer

Our third quarter performance marks another important milestone in Neurocrine's evolution, with net product sales exceeding $1 billion for the first time, driven by strong underlying demand across our diversified portfolio of first-in-class medicines.

TMDX logo18TMDXTransMedics Group, Inc.Nov 5, 2026
Mkt Cap$3.3B
EPS Act.$0.51
EPS Est.$0.30
Surprise+71.4%
Reaction+21.3%
SectorHealthcare
Waleed Hassanein, MD, President and Chief Executive Officer

The third quarter of 2026 was the strongest in TransMedics' history, with record revenue and record case volume. Importantly, we delivered these results despite typical third quarter seasonality and before any contribution from ENHANCE Part B or DENOVO.

PGNY logo19PGNYProgyny, Inc.Nov 4, 2026
Mkt Cap$2.8B
EPS Act.$0.52
EPS Est.$0.31
Surprise+66.1%
Reaction+18.3%
SectorHealthcare
Pete Anevski, Chief Executive Officer

We're exceptionally pleased with the results of our most recent selling season, where our momentum extended even into its latest stages, yielding 1.3 million new covered lives, our most ever in a single season

SRPT logo20SRPTSarepta Therapeutics, Inc.Nov 5, 2026
Mkt Cap$1.5B
EPS Act.$0.13
EPS Est.$0.08
Surprise+64.6%
Reaction-6.2%
SectorHealthcare
Michael Severino, M.D., chief executive officer

After my first 90 days at Sarepta, I believe the fundamental strengths that attracted me to the company remain firmly intact: a durable Duchenne franchise, a promising pipeline with the potential to deliver differentiated medicines, and the financial strength to invest in our highest-value opportunities.

INNV logo21INNVInnovAge Holding Corp.Nov 3, 2026
Mkt Cap$1.2B
EPS Act.$0.14
EPS Est.$0.09
Surprise+63.0%
Reaction+9.8%
SectorHealthcare
Patrick Blair, Chief Executive Officer

We are pleased with our strong start to fiscal 2027, as continued census growth along with disciplined clinical and operational execution drove strong financial performance.

LFST logo22LFSTLifeStance Health Group, Inc.Nov 5, 2026
Mkt Cap$5.3B
EPS Act.$0.06
EPS Est.$0.04
Surprise+62.6%
Reaction-3.1%
SectorHealthcare
Dave Bourdon, CEO

The team delivered a tremendous quarter, with execution across the business driving results that once again exceeded our expectations," said Dave Bourdon, CEO of LifeStance.

INSP logo23INSPInspire Medical Systems, Inc.Nov 2, 2026
Mkt Cap$1.7B
EPS Act.$0.14
EPS Est.$0.09
Surprise+60.9%
Reaction-7.9%
SectorHealthcare
Tim Herbert, Chairman and CEO

Looking further ahead, we were also pleased with the AMA Editorial Panel's September approval of a new CPT code for single lead HGNS devices, including the Inspire V system.

ETON logo24ETONEton Pharmaceuticals, Inc.Nov 5, 2026
Mkt Cap$1.7B
EPS Act.$0.50
EPS Est.$0.31
Surprise+60.0%
Reaction+11.3%
SectorHealthcare
Sean Brynjelsen, CEO

Eton delivered another record quarter, with revenue of $57.9 million, up 158% year over year, and surpassed our $200 million annualized revenue run rate goal five quarters ahead of schedule.

AXGN logo25AXGNAxoGen, Inc.Oct 28, 2026
Mkt Cap$3.1B
EPS Act.$0.21
EPS Est.$0.13
Surprise+59.9%
Reaction+31.5%
SectorHealthcare
Michael Dale, President and CEO

We are delighted with our third-quarter and year-to-date revenue performance and the progress we continue to make across each of Axogen's strategic plan priorities,

Biggest EPS Misses17

Ranked by EPS miss % (worst first). Price reaction = day after report.

#SymbolCompanySectorDateEPS ActualEPS Est.SurprisePrice Reaction
1PTC Therapeutics, Inc.HealthcareOct 29, 2026-$0.62↑ Raised$0.14-532%-7.0%
Matthew B. Klein, M.D., Chief Executive Officer

We delivered another strong quarter of record product revenue led by the continued momentum of the Sephience launch, putting us firmly on track to achieve our cash flow breakeven milestone this year.

2Liquidia CorporationHealthcareNov 10, 2026-$2.64$0.96-375%+7.4%
Dr. Roger Jeffs, Chief Executive Officer

Five quarters after launch, YUTREPIA has rapidly established a preferred product profile because physicians value the control and flexibility it gives them over each patient's therapy.

3Hims & Hers Health, Inc.HealthcareNov 9, 2026-$0.14~ Mixed$0.06-349%-16.6%
Andrew Dudum, co-founder and CEO

In healthcare, whoever owns the customer relationship wins, and that's exactly what we're building toward at Hims & Hers. Today, customers want real choice, real value, and a care team that knows them.

4Innoviva, Inc.HealthcareNov 4, 2026-$1.03— Maintained$0.52-300%-8.1%
Pavel Raifeld, Chief Executive Officer

IST delivered another quarter of excellent growth, with U.S. net product sales increasing 45% year-over-year to $43.3 million, keeping us on track to achieve our 2026 guidance of at least $150 million in U.S. net product sales.

5UroGen Pharma Ltd.HealthcareNov 4, 2026-$0.03↓ Lowered$0.11-128%-25.2%
Liz Barrett, President and Chief Executive Officer

We delivered another strong quarter of execution, with ZUSDURI continuing to scale as growing repeat utilization, expanding community adoption, and broader physician engagement reinforce our confidence in the long-term commercial opportunity.

6Arcutis Biotherapeutics, Inc.HealthcareNov 4, 2026$0.06↑ Raised$0.18-66.7%-15.6%
Frank Watanabe, president and chief executive officer

Yet another strong quarter of performance reflects the consistent execution of our corporate strategy and further strengthens our financial position.

7Harmony Biosciences Holdings, Inc.HealthcareNov 4, 2026$0.81— Maintained$1.09-25.7%-12.3%
Jeffrey Dayno, MD, President and CEO

As I prepare to transition the President and CEO role to Peter on January 1, I believe Harmony is operating from a position of strength, with a durable and growing WAKIX franchise, the financial flexibility to invest in innovation

8Integer Holdings CorporationHealthcareOct 29, 2026$1.34$1.68-20.2%-0.0%
9Penumbra, Inc.HealthcareOct 29, 2026$1.07$1.20-10.8%+0.2%
10DENTSPLY SIRONA Inc.HealthcareNov 5, 2026$0.29~ Mixed$0.31-6.1%-11.2%
Dan Scavilla, President and Chief Executive Officer

We continued to make progress on our Return-to-Growth Action Plan in the third quarter despite challenging industry-wide conditions

11Alphatec Holdings, Inc.HealthcareOct 29, 2026$0.09~ Mixed$0.10-5.4%-38.1%
Pat Miles, Chairman and Chief Executive Officer

Third-quarter revenue fell short of our expectations, primarily due to lower biologics attachment, said Pat Miles, Chairman and Chief Executive Officer.

12LeMaitre Vascular, Inc.HealthcareNov 4, 2026$0.65— Maintained$0.69-5.3%+3.6%
George LeMaitre, Chairman/CEO

We expect 2026 to be another year of healthy sales (+11%) and EPS growth (+18%). Biologics continue to drive sales due to Artegraft's international launch and the continued growth of RestoreFlow Allografts.

13United Therapeutics CorporationHealthcareNov 4, 2026$5.71$6.01-5.0%+1.2%
Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer

United Therapeutics is entering a period of extraordinary growth. We are advancing a portfolio of new therapies designed to exponentially increase the number of patients we can serve,

14Bio-Techne CorporationHealthcareNov 4, 2026$0.42$0.44-4.5%0.0%
15Pacira BioSciences, Inc.HealthcareNov 5, 2026$0.72$0.75-4.3%+0.1%
16TG Therapeutics, Inc.HealthcareNov 9, 2026$0.35$0.36-2.6%+5.9%
17The Pennant Group, Inc.HealthcareNov 4, 2026$0.35— Maintained$0.36-2.1%-2.9%
Brent Guerisoli, CEO

Pennant delivered a solid quarter and strong year-over-year improvement across the organization, said Brent Guerisoli, the Company's Chief Executive Officer.

PTCT logo1PTCTPTC Therapeutics, Inc.Oct 29, 2026
Mkt Cap$5.0B
EPS Act.-$0.62
EPS Est.$0.14
Surprise-532%
Reaction-7.0%
SectorHealthcare
Matthew B. Klein, M.D., Chief Executive Officer

We delivered another strong quarter of record product revenue led by the continued momentum of the Sephience launch, putting us firmly on track to achieve our cash flow breakeven milestone this year.

LQDA logo2LQDALiquidia CorporationNov 10, 2026
Mkt Cap$5.0B
EPS Act.-$2.64
EPS Est.$0.96
Surprise-375%
Reaction+7.4%
SectorHealthcare
Dr. Roger Jeffs, Chief Executive Officer

Five quarters after launch, YUTREPIA has rapidly established a preferred product profile because physicians value the control and flexibility it gives them over each patient's therapy.

HIMS logo3HIMSHims & Hers Health, Inc.Nov 9, 2026
Mkt Cap$3.8B
EPS Act.-$0.14
EPS Est.$0.06
Surprise-349%
Reaction-16.6%
SectorHealthcare
Andrew Dudum, co-founder and CEO

In healthcare, whoever owns the customer relationship wins, and that's exactly what we're building toward at Hims & Hers. Today, customers want real choice, real value, and a care team that knows them.

INVA logo4INVAInnoviva, Inc.Nov 4, 2026
Mkt Cap$1.4B
EPS Act.-$1.03
EPS Est.$0.52
Surprise-300%
Reaction-8.1%
SectorHealthcare
Pavel Raifeld, Chief Executive Officer

IST delivered another quarter of excellent growth, with U.S. net product sales increasing 45% year-over-year to $43.3 million, keeping us on track to achieve our 2026 guidance of at least $150 million in U.S. net product sales.

URGN logo5URGNUroGen Pharma Ltd.Nov 4, 2026
Mkt Cap$1.5B
EPS Act.-$0.03
EPS Est.$0.11
Surprise-128%
Reaction-25.2%
SectorHealthcare
Liz Barrett, President and Chief Executive Officer

We delivered another strong quarter of execution, with ZUSDURI continuing to scale as growing repeat utilization, expanding community adoption, and broader physician engagement reinforce our confidence in the long-term commercial opportunity.

ARQT logo6ARQTArcutis Biotherapeutics, Inc.Nov 4, 2026
Mkt Cap$3.5B
EPS Act.$0.06
EPS Est.$0.18
Surprise-66.7%
Reaction-15.6%
SectorHealthcare
Frank Watanabe, president and chief executive officer

Yet another strong quarter of performance reflects the consistent execution of our corporate strategy and further strengthens our financial position.

HRMY logo7HRMYHarmony Biosciences Holdings, Inc.Nov 4, 2026
Mkt Cap$1.9B
EPS Act.$0.81
EPS Est.$1.09
Surprise-25.7%
Reaction-12.3%
SectorHealthcare
Jeffrey Dayno, MD, President and CEO

As I prepare to transition the President and CEO role to Peter on January 1, I believe Harmony is operating from a position of strength, with a durable and growing WAKIX franchise, the financial flexibility to invest in innovation

ITGR logo8ITGRInteger Holdings CorporationOct 29, 2026
Mkt Cap$4.3B
EPS Act.$1.34
EPS Est.$1.68
Surprise-20.2%
Reaction-0.0%
SectorHealthcare
PEN logo9PENPenumbra, Inc.Oct 29, 2026
Mkt Cap$12.6B
EPS Act.$1.07
EPS Est.$1.20
Surprise-10.8%
Reaction+0.2%
SectorHealthcare
XRAY logo10XRAYDENTSPLY SIRONA Inc.Nov 5, 2026
Mkt Cap$1.7B
EPS Act.$0.29
EPS Est.$0.31
Surprise-6.1%
Reaction-11.2%
SectorHealthcare
Dan Scavilla, President and Chief Executive Officer

We continued to make progress on our Return-to-Growth Action Plan in the third quarter despite challenging industry-wide conditions

ATEC logo11ATECAlphatec Holdings, Inc.Oct 29, 2026
Mkt Cap$1.1B
EPS Act.$0.09
EPS Est.$0.10
Surprise-5.4%
Reaction-38.1%
SectorHealthcare
Pat Miles, Chairman and Chief Executive Officer

Third-quarter revenue fell short of our expectations, primarily due to lower biologics attachment, said Pat Miles, Chairman and Chief Executive Officer.

LMAT logo12LMATLeMaitre Vascular, Inc.Nov 4, 2026
Mkt Cap$1.7B
EPS Act.$0.65
EPS Est.$0.69
Surprise-5.3%
Reaction+3.6%
SectorHealthcare
George LeMaitre, Chairman/CEO

We expect 2026 to be another year of healthy sales (+11%) and EPS growth (+18%). Biologics continue to drive sales due to Artegraft's international launch and the continued growth of RestoreFlow Allografts.

UTHR logo13UTHRUnited Therapeutics CorporationNov 4, 2026
Mkt Cap$24.5B
EPS Act.$5.71
EPS Est.$6.01
Surprise-5.0%
Reaction+1.2%
SectorHealthcare
Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer

United Therapeutics is entering a period of extraordinary growth. We are advancing a portfolio of new therapies designed to exponentially increase the number of patients we can serve,

TECH logo14TECHBio-Techne CorporationNov 4, 2026
Mkt Cap$11.4B
EPS Act.$0.42
EPS Est.$0.44
Surprise-4.5%
Reaction0.0%
SectorHealthcare
PCRX logo15PCRXPacira BioSciences, Inc.Nov 5, 2026
Mkt Cap$1.4B
EPS Act.$0.72
EPS Est.$0.75
Surprise-4.3%
Reaction+0.1%
SectorHealthcare
TGTX logo16TGTXTG Therapeutics, Inc.Nov 9, 2026
Mkt Cap$10.1B
EPS Act.$0.35
EPS Est.$0.36
Surprise-2.6%
Reaction+5.9%
SectorHealthcare
PNTG logo17PNTGThe Pennant Group, Inc.Nov 4, 2026
Mkt Cap$1.2B
EPS Act.$0.35
EPS Est.$0.36
Surprise-2.1%
Reaction-2.9%
SectorHealthcare
Brent Guerisoli, CEO

Pennant delivered a solid quarter and strong year-over-year improvement across the organization, said Brent Guerisoli, the Company's Chief Executive Officer.